Decreased cerebrospinal fluid TNFRSF8 (sCD30) confirmed as a biomarker of Huntington’s disease progression
In Huntington’s disease (HD), clinical heterogeneity in age at onset and disease progression poses demands on precision medicine approaches. Biofluid biomarkers are needed to monitor disease progression, but may also provide insights into pathogenic mechanisms and support the development of disease-modifying therapies...